Chinese couple on trial for selling India-made cancer drugs

Image
Press Trust of India Beijing
Last Updated : Nov 11 2014 | 12:35 PM IST
A Chinese couple has been put on trial for allegedly selling low cost India-made cancer drugs, highlighting persistent calls for opening China's pharma sector to cheaper Indian drugs.
The couple in China's Nanjing city in Jiangsu Province recently stood trial for selling cancer medication bought in India, official media reported.
Zhou Rongqiang, Judge of the local court, told state-run Global Times yesterday that the couple, Zhao Hongjiang and his wife, Ma Yalin, were accused of purchasing medicines from India, transporting them to China, and selling them online.
Indian-made generic cancer drugs, often containing the same active ingredients as the patented medicines they are based on, sell at enormous discount compared with their patented counterparts, the report said.
The vast majority of these drugs are not approved for sale in China.
"Selling medicines produced overseas requires a certification by China's drug watchdog. If not, the drugs are seen as fake," Zhou said.
In the court, Zhao said that he was trying to save people's lives, and that most of the drugs were brought for his friends instead for sale, local daily Modern Express reported.
The case highlights India's persistent calls for China to open up its markets for Indian pharma products which have been widely approved for use in various countries to make them available for its citizens as well as to address the trade imbalance between the two countries.
China says there are barriers but Indian pharmaceutical firms complain of lengthy procedures requiring years of testing for the drugs which have been approved in various markets abroad.
Medicines in China mostly controlled by multinational markets are highly expensive making it extremely difficult for vast majority of Chinese to afford them.
As a result number of Chinese traders are smuggling the Indian drugs into Chinese markets.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 11 2014 | 12:35 PM IST

Next Story